Phase 2 Study of Loncastuximab Tesirine and Mosunetuzumab for Treating Relapsed or Refractory Diffuse Large B-Cell Lymphoma

What this Trial Is About

Researchers are evaluating the safety and effectiveness of a combination of loncastuximab tesirine and mosunetuzumab in patients with diffuse large B-cell lymphoma that has returned or does not respond to prior treatments. This phase II trial aims to understand how well this combination works in treating relapsed or refractory cases of this lymphoma, a type of blood cancer. The study also explores genetic and immune factors that may affect response and resistance to the treatment. Participants receive intravenous infusions of loncastuximab tesirine, a targeted antibody linked to a toxic agent designed to kill cancer cells, along with mosunetuzumab, an antibody that may prevent cancer cell growth and spread. The treatment includes diagnostic procedures such as positron emission tomographycomputed tomography PETCT scans, biopsies, and blood sample collections. These assessments help monitor disease status and treatment effects. During the study, participants undergo regular scans, biopsies, and blood tests to evaluate treatment response and safety. Researchers measure outcomes including overall response rate, complete response rate, duration of response, progression-free survival, and overall survival, with follow-up assessments continuing up to two years after the last dose. Safety and tolerability are closely monitored, especially within 30 days following the final treatment. The total participation time varies depending on treatment response and follow-up schedules.

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma